Prognostic value of pentraxin-3 level in patients with STEMI and its relationship with heart failure and markers of oxidative stress.
OBJECTIVE
Pentraxin-3 (PTX3) appears to have a cardioprotective effect through a positive influence against postreperfusion damage. This study assesses the prognostic value of PTX3 level and its relationship with clinical parameters and markers of oxidative stress and nitric oxide metabolism in patients with ST-elevation myocardial infarction (STEMI).


METHODS
Plasma/serum levels of several biomarkers of inflammation and oxidative stress and nitrite/nitrate were assessed upon admission and 24 h after STEMI onset in patients treated by primary percutaneous coronary intervention.


RESULTS
ROC analysis showed that plasma PTX3 at 24 h was a strong predictor of 30-day and 1-year mortality and independent predictor of combined end-point of left ventricle dysfunction or mortality in 1 year. The inflammatory response expressed by PTX3 had a significant relationship with age, heart failure, infarct size, impaired flow in the infarct-related artery, and renal function and positively correlated with neopterin, TNF-α, 8-hydroxy-2'-deoxyguanosine, and nitrite/nitrate.


CONCLUSIONS
Plasma PTX3 at 24 h after STEMI onset is a strong predictor of 30-day and 1-year mortality. PTX3 as a single biomarker is comparable with currently used scoring systems (TIMI or GRACE) or B-type natriuretic peptide. PTX3 is also an independent predictor of combined end-point of left ventricle dysfunction or mortality in 1 year.
Department of Biochemistry, Faculty of Medicine, Masaryk University, 625 00 Brno, Czech Republic.
Marie
M
Tomandlova
Institute of Biostatistics and Analyses, Masaryk University, 625 00 Brno, Czech Republic.
Jiri
J
Jarkovsky
Department of Biochemistry, Faculty of Medicine, Masaryk University, 625 00 Brno, Czech Republic.
Josef
J
Tomandl
Department of Cardiovascular Disease, International Clinical Research Center, St. Anne's University Hospital, 656 91 Brno, Czech Republic ; Department of Cardiology, University Hospital Brno, 625 00 Brno, Czech Republic ; Faculty of Medicine, Masaryk University, 625 00 Brno, Czech Republic.
Lenka
L
Kubkova
Department of Cardiology, University Hospital Brno, 625 00 Brno, Czech Republic ; Faculty of Medicine, Masaryk University, 625 00 Brno, Czech Republic.
Petr
P
Kala
Institute of Biostatistics and Analyses, Masaryk University, 625 00 Brno, Czech Republic.
Simona
0000-0003-4645-641X
S
Littnerova
Faculty of Medicine, Masaryk University, 625 00 Brno, Czech Republic ; Department of Biochemistry, University Hospital Brno, 625 00 Brno, Czech Republic.
Jana
J
Gottwaldova
Department of Cardiology, University Hospital Brno, 625 00 Brno, Czech Republic ; Faculty of Medicine, Masaryk University, 625 00 Brno, Czech Republic.
Petr
P
Kubena
Department of Cardiology, University Hospital Brno, 625 00 Brno, Czech Republic ; Faculty of Medicine, Masaryk University, 625 00 Brno, Czech Republic.
Eva
E
Ganovska
Department of Cardiology, University Hospital Brno, 625 00 Brno, Czech Republic ; Faculty of Medicine, Masaryk University, 625 00 Brno, Czech Republic.
Martin
M
Poloczek
Department of Cardiovascular Disease, International Clinical Research Center, St. Anne's University Hospital, 656 91 Brno, Czech Republic ; Department of Cardiology, University Hospital Brno, 625 00 Brno, Czech Republic ; Faculty of Medicine, Masaryk University, 625 00 Brno, Czech Republic.
Jindrich
J
Spinar
Department of Internal Medicine, University Hospital, 4031 Basel, Switzerland.
Christian
C
Mueller
Department of Anesthesiology and Critical Care Medicine, Saint Luis Lariboisière University Hospital, 75475 Paris, France ; Cardiac Diseases and Biomarkers, INSERM UMR 942, Saint Luis Lariboisière University Hospital, 75475 Paris, France.
Alexandre
A
Mebazaa
Institute of Pathological Physiology, Faculty of Medicine, Masaryk University, 625 00 Brno, Czech Republic.
Monika
M
Pavkova Goldbergova
Department of Cardiovascular Disease, International Clinical Research Center, St. Anne's University Hospital, 656 91 Brno, Czech Republic ; Department of Cardiology, University Hospital Brno, 625 00 Brno, Czech Republic ; Faculty of Medicine, Masaryk University, 625 00 Brno, Czech Republic.
Jiri
J
Parenica
D000080242:8-Hydroxy-2'-Deoxyguanosine; D000368:Aged; D015415:Biomarkers / Q000097:blood; D002097:C-Reactive Protein / Q000378:metabolism*; D003849:Deoxyguanosine / Q000031:analogs & derivatives / Q000097:blood; D005260:Female; D006333:Heart Failure / Q000097:blood* / Q000401:mortality; D006801:Humans; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000097:blood* / Q000401:mortality; D020097:Natriuretic Peptide, Brain / Q000097:blood; D019798:Neopterin / Q000097:blood; D009573:Nitrites / Q000097:blood; D018384:Oxidative Stress; D011237:Predictive Value of Tests; D000683:Serum Amyloid P-Component / Q000378:metabolism*; D019210:Troponin I / Q000097:blood; D014409:Tumor Necrosis Factor-alpha / Q000097:blood; D000099153:Pentraxins
D000080242:8-Hydroxy-2'-Deoxyguanosine; D015415:Biomarkers; D002097:C-Reactive Protein; D003849:Deoxyguanosine; D020097:Natriuretic Peptide, Brain; D019798:Neopterin; D009573:Nitrites; D000683:Serum Amyloid P-Component; D019210:Troponin I; D014409:Tumor Necrosis Factor-alpha; D000099153:Pentraxins